Final FDA rule on device, drug and biologic combos is available

01/23/2013 | MassDevice.com (Boston)

A final rule released this week by the FDA outlines current good manufacturing practice standards for products that combine drugs, medical devices and biologics. The rule aims to clarify the CGMP criteria for new and existing combination products that are sold together or are "single-entity" combinations.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC